Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Saar Gill

Showing results (11-20 of 92) with videos related to

Pageof 10
Sort By:
Blood Advances|September 28, 2021
The promise and perils of immunotherapyStefanie Lesch, Saar Gill
Frontiers in Oncology|May 22, 2020
CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future DirectionsSherly Mardiana, Saar Gill
Leukemia & Lymphoma|October 26, 2020
Long-term outcomes in patients with AML achieving first complete remission: confronting the double-hit of survivorshipStrachan Mackenzie, Saar Gill
Hematology/Oncology Clinics of North America|July 13, 2023
Chimeric Antigen Receptor T Cells in Acute Myeloid LeukemiaKatherine Cummins, Saar Gill
Expert Opinion on Biological Therapy|February 3, 2015
How to train your T cell: genetically engineered chimeric antigen receptor T cells versus bispecific T-cell engagers to target CD19 in B acute lymphoblastic leukemiaMarco Ruella, Saar Gill
Leukemia & Lymphoma|September 14, 2017
Anti-CD123 chimeric antigen receptor T-cells (CART): an evolving treatment strategy for hematological malignancies, and a potential ace-in-the-hole against antigen-negative relapseKatherine D Cummins, Saar Gill
Expert Opinion on Biological Therapy|November 23, 2013
CAR-modified anti-CD19 T cells for the treatment of B-cell malignancies: rules of the roadSaar Gill, David L Porter
Immunological Reviews|December 17, 2014
Going viral: chimeric antigen receptor T-cell therapy for hematological malignanciesSaar Gill, Carl H June
Nature Biotechnology|October 23, 2023
Hypoimmune cells resist rejection in monkeysAsuncion Borrero Borrego, Saar Gill
Annual Review of Medicine|November 6, 2012
Reduced-intensity hematopoietic stem cell transplants for malignancies: harnessing the graft-versus-tumor effectSaar Gill, David L Porter
Pageof 10

Showing results (11-20 of 92) with videos related to

Sort By:
Pageof 10
Blood Advances|September 28, 2021
The promise and perils of immunotherapyStefanie Lesch, Saar Gill
Frontiers in Oncology|May 22, 2020
CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future DirectionsSherly Mardiana, Saar Gill
Leukemia & Lymphoma|October 26, 2020
Long-term outcomes in patients with AML achieving first complete remission: confronting the double-hit of survivorshipStrachan Mackenzie, Saar Gill
Hematology/Oncology Clinics of North America|July 13, 2023
Chimeric Antigen Receptor T Cells in Acute Myeloid LeukemiaKatherine Cummins, Saar Gill
Expert Opinion on Biological Therapy|February 3, 2015
How to train your T cell: genetically engineered chimeric antigen receptor T cells versus bispecific T-cell engagers to target CD19 in B acute lymphoblastic leukemiaMarco Ruella, Saar Gill
Leukemia & Lymphoma|September 14, 2017
Anti-CD123 chimeric antigen receptor T-cells (CART): an evolving treatment strategy for hematological malignancies, and a potential ace-in-the-hole against antigen-negative relapseKatherine D Cummins, Saar Gill
Expert Opinion on Biological Therapy|November 23, 2013
CAR-modified anti-CD19 T cells for the treatment of B-cell malignancies: rules of the roadSaar Gill, David L Porter
Immunological Reviews|December 17, 2014
Going viral: chimeric antigen receptor T-cell therapy for hematological malignanciesSaar Gill, Carl H June
Nature Biotechnology|October 23, 2023
Hypoimmune cells resist rejection in monkeysAsuncion Borrero Borrego, Saar Gill
Annual Review of Medicine|November 6, 2012
Reduced-intensity hematopoietic stem cell transplants for malignancies: harnessing the graft-versus-tumor effectSaar Gill, David L Porter
Pageof 10